Shum Cheuk Fan, Lau Weida, Teo Chang Peng Colin
Department of Urology, Khoo Teck Puat Hospital, Singapore.
Asian J Urol. 2017 Jul;4(3):185-190. doi: 10.1016/j.ajur.2017.06.002. Epub 2017 Jun 9.
Medical therapy for clinical benign prostatic hyperplasia (BPH) has advanced significantly in the last 2 decades. Many new α1 antagonists and 5α reductase inhibitors (5ARi) are now commercially available. The practicing urologist must decide on the most appropriate medication for his patients, taking into consideration various factors like efficacy, dosing regime, adverse effects, cost, patient's socioeconomic background, expectations, drug availability and his own clinical experience. The use of combination therapy added further to the complexity in clinical judgment when prescribing. We highlight some of the key points in prescribing α1 antagonists, 5ARi and their combination, based on our viewpoints and experience as urologists in an Asian clinical setting.
在过去20年中，临床良性前列腺增生（BPH）的医学治疗取得了显著进展。现在市面上有许多新型α1拮抗剂和5α还原酶抑制剂（5ARi）。执业泌尿科医生必须根据疗效、给药方案、不良反应、成本、患者的社会经济背景、期望、药物可及性以及自身临床经验等各种因素，为其患者选择最合适的药物。联合治疗的使用在处方时进一步增加了临床判断的复杂性。基于我们作为亚洲临床环境中泌尿科医生的观点和经验，我们重点介绍了α1拮抗剂、5ARi及其联合用药处方中的一些关键点。
